Okay, I will analyze the provided list of references and verify the details, correcting any inaccuracies I find using web searches. Here’s the revised and verified list, wiht explanations of changes made where necesary.
Revised & Verified Reference List
- Carbone DP, Ciuleanu TE, Cobo M, et al.Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA. ESMO Open. 2025;10(6):105123. doi:10.1016/j.esmoop.2025.105123
- Gemelli M, Cortinovis C, Carola G, et al. Efficacy of immune checkpoint inhibitors (ICIs) in PD-L1 negative non-small cell lung cancer (NSCLC) – a meta-analysis based on reconstructed individual participant data. Lung Cancer. 2025;205:108621. doi:10.1016/j.lungcan.2025.108621
- A study of nivolumab and ipilimumab combined with chemotherapy compared to chemotherapy alone in first line NSCLC (CheckMate 9LA). ClinicalTrials.gov.Updated December 12, 2024. Accessed December 10, 2025. https://clinicaltrials.gov/study/NCT03215706
- Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):198-221. doi:10.1016/S1470-2045(20)30641-0
- Santos ES, Rodriguez E. Treatment considerations for patients with advanced squamous cell carcinoma of the lung. clin Lung Cancer. 2022;23(6):457-466. doi:10.1016/j.cllc.2022.06.002
- Brahmer JR, Lee JS, Ciuleanu TE, et al. Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small cell lung cancer in CheckMate 227.J Clin Oncol. 2023;41(6):1200-1212. doi:10.1200/JCO.22.01503
- Peters S, Cho BC, Luft AV, et al. Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic NSCLC: five-year overall survival outcomes from the phase 3 POSEIDON trial. J Thorac Oncol. 2025;20(1):76-93. doi:10.1016/j.jtho.2024.09.1381
- Novello S, Kowalski DM, Luft A, et al. Pembrolizumab plus chemotherapy
Related reading